tradingkey.logo
tradingkey.logo
Search

Vanda Pharmaceuticals Inc

VNDA
Add to Watchlist
5.800USD
-0.160-2.68%
Close 06/18, 16:00ETQuotes delayed by 15 min
348.78MMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
7.60
Change
0
The current earnings forecast score of Vanda Pharmaceuticals Inc is 7.60, ranking 283 out of 389 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 20.00 and a low of 5.00.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
14.125
Target Price
+143.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Vanda Pharmaceuticals Inc
VNDA
4
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Vanda Pharmaceuticals Inc's expected revenue for the next quarter?

Vanda Pharmaceuticals Inc's expected revenue is 61.92M.

What is Vanda Pharmaceuticals Inc's price target?

Analysts forecast that Vanda Pharmaceuticals Inc's price target is USD 11.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 5.00.

How have Vanda Pharmaceuticals IncVNDA's recent earnings per share performed?

The market expectation was USD -0.82, while Vanda Pharmaceuticals IncVNDA's earnings per share (EPS) for the previous quarter was USD -2.39. EPS for the next quarter is expected at USD -0.59.

What is the analyst rating for Vanda Pharmaceuticals Inc?

Based on the ratings of Vanda Pharmaceuticals Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI